TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04516980

Intervention type: OTHER
Intervention: Questionnaires administration
Description: Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints.

Intervention type: OTHER
Intervention: Questionnaires administration
Description: Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints.
Study: NCT06080945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacist-led patient-centered medication therapy management
Description: The intervention group will receive a pharmacist-driven discharge counseling on budesonide, an inhaled glucocorticoid, from recruitment, until 12 months.
Study: NCT06200909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: 8-week mindfulness meditation program, based on Kabat-Zinn's MBSR program and modified for caregivers. The intervention will be led by MBSR-trained facilitators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: A lecture-style program based on the 10 KeysTM to Healthy Aging Course, an evidence-based program for older adults. The program will be delivered by a facilitator experienced in delivering similar content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait list control
Description: Participants will receive two hours of respite from their caregiving responsibilities per week, for eight weeks. They will be given the opportunity to participate in either the MM or the PSY condition following completion of testing.
Study: NCT04678804

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mucogingival surgery for single recession coverage
Description: The control group will be treated with a coronally advanced flap with vertical incisions (CAF) associated to an autologous connective tissue graft. The graft will be harvested from the palate in the area apical to the gingival margin of the second molar with an epithelial-connective harvesting technique to obtain a connective graft of 1 mm in thickness.~Subsequently, the graft will be shaped in order to match height and width of the recipient site on the recession according to the technique proposed by Zucchelli in 2003. The test group will receive the same flap design with the same technique, then the porcine derived xenogeneic graft will be shaped in order to match height and width of the recipient site on the recession. In particular, the matrix will be reduced in thickness as suggested by the manufacturer to obtain a standardized thickness of 3 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucogingival surgery for single recession coverage
Description: The control group will be treated with a coronally advanced flap with vertical incisions (CAF) associated to an autologous connective tissue graft. The graft will be harvested from the palate in the area apical to the gingival margin of the second molar with an epithelial-connective harvesting technique to obtain a connective graft of 1 mm in thickness.~Subsequently, the graft will be shaped in order to match height and width of the recipient site on the recession according to the technique proposed by Zucchelli in 2003. The test group will receive the same flap design with the same technique, then the porcine derived xenogeneic graft will be shaped in order to match height and width of the recipient site on the recession. In particular, the matrix will be reduced in thickness as suggested by the manufacturer to obtain a standardized thickness of 3 mm.
Study: NCT06432582

Intervention type: DIAGNOSTIC_TEST
Intervention: hepatomiR
Description: hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).
Study: NCT06252545

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: semistructured interviews
Description: Black subjects with pancreatic cancer will provide insight on their experience discussing clinical trials and preferences for communicating clinical trial information

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: feedback
Description: Black subjects with pancreatic cancer will provide feedback on mHealth app prototype.
Study: NCT06029439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-335140
Description: Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.
Study: NCT06107387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binge Eating Self-help for Teens
Description: Guided self-help intervention
Study: NCT05516498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
Description: placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: zibotentan (dose B) + dapagliflozin
Description: zibotentan capsule~dapagliflozin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
Description: placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: placebo (matching zibotentan capsule) + dapagliflozin
Description: placebo capsule (matching zibotentan capsule)~dapagliflozin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: zibotentan (dose A) + dapagliflozin
Description: zibotentan capsule~dapagliflozin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: zibotentan (dose B) + dapagliflozin
Description: zibotentan capsule~dapagliflozin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: zibotentan (dose C) + dapagliflozin
Description: zibotentan capsule~dapagliflozin tablet
Study: NCT05677841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercise+lifestyle recommendation
Description: Exercise program was given both spinal stabilization exercises focusing on the pelvic floor 3 days a week for eight weeks and a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle recommendations
Description: The control group will be given a booklet related to the lower urinary system symptoms, the structure of the pelvic floor and healthy behavioral strategies recommendations (fluid intake, diet, weight control etc. )
Study: NCT06207864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue, blood, saliva, and stool samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Return of Results
Description: Receive results

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Surveys and Interviews
Study: NCT06154044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34+ stem cell therapy
Description: After 5-days GCSF stimulation all patients will undergo apheresis to obtain CD34+ cell which will subsequently be injected in the target coronary artery using microcatheter.
Study: NCT05694689

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D supplementation with feedings in the first 28 days after birth
Description: 800 IU/day Vitamin D supplementation until 400 IU/ day are provided as part of usual care. At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
Study: NCT02738073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study: NCT05607927

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Parks surgery
Description: Parks surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PE-Bacon surgery
Description: PE-Bacon surgery
Study: NCT05667909

Intervention type: DRUG
Intervention: Rituximab
Description: 375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
Study: NCT05694689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices
Study: NCT05966415

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Endocalyx Pro
Description: 4 capsules once daily OR 2 capsules twice daily.
Study: NCT05951881

Intervention type: OTHER
Intervention: Emergency Care Unit - medicines
Description: The same group of patients admitted to the emergency room will respond separately to a pharmacist and a pharmacy assistant about their daily medication.~The two medical records will be compared in order to evaluate the work of the pharmacy assistant on the basis of 3 sources :~* the Electronic Medical Record~* the patient's medication history~* the reference pharmacy
Study: NCT05966415

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 capsules once daily OR 2 capsules twice daily
Study: NCT05901402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic and resistance exercise
Description: The experimental group performed aerobic resistance exercise during pregnancy every day.
Study: NCT05983354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide and ibuprofen
Description: 10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml normal saline IV administered over 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous metoclopramide and ketorolac
Description: 10 mg of metoclopramide IV in 50 ml normal saline, 10 mg ketorolac IV in 50 ml normal saline administered over 15 minutes, with 2 placebo tablets.
Study: NCT06432803

Intervention type: OTHER
Intervention: PET-Scan analysis
Description: Investigate and determine the clinical value of different cortex/striatal metabolic ratio patterns in each antibody-specific subtype of autoimmune encephalitis

Intervention type: OTHER
Intervention: PET-Scan analysis
Description: Investigate and determine the clinical value of different cortex/striatal metabolic ratio patterns in each antibody-specific subtype of autoimmune encephalitis
Study: NCT05516862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dragons acupuncture
Description: The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 needles placed in head, upper back, lower back and ankles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dragons acupressure
Description: The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 small acupressure adhesive bandages placed on head, upper back, lower back and ankles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dragons placebo
Description: The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and the doctor will touch 7 points on head, upper back, lower back and ankles.
Study: NCT06632964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic adenovirus injection solution of VT-101
Description: Active ingredient: VT-101 recombinant oncolytic adenovirus Specifications: 2×10\^10 IFU/ml, 0.5ml/ capsule Method of administration: intravesical perfusion
Study: NCT06170216

Intervention type: DRUG
Intervention: immunochemotherapies
Description: Observing different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), which are chosen by investigators, such as RCHOP, BR, RCVP, etc.
Study: NCT06328049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib Injection
Description: Patients with lung adenocarcinoma were given Trilaciclib combined with pemetrexed and carboplatin, Q3W; For patients with lung squamous cell carcinoma,Trilaciclib combined with paclitaxel/albumin-bound paclitaxel and carboplatin, Q3W. From cycle 2 onwards, patients chose whether to use trasylol with chemotherapy.
Study: NCT04805112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of multiple self-tests
Description: Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
Study: NCT06525090

Intervention type: OTHER
Intervention: no intervention-child-administered questionnaires
Description: The implementation of the research was started after getting approval from Mugla Sıtkı Kocman University Health Sciences Ethics Committee and TR Ministry of National Education Research, Competition and Social Activity. The purpose of the study was explained by the researchers to the administrators of the schools where the study was conducted and planning was made with the school administration. The data were collected in 15-20 minutes from the students who agreed to participate in the study during the course hours deemed appropriate by the administration. The purpose of the study and how to fill in the measurement tools was explained to the students, and it was stated that the research data would be kept confidential and used only by the researcher. The self-administered questionnaires were filled out on the paper. Verbal consent was obtained from the students participating in the study and written informed consent was obtained from their parents.
Study: NCT06525584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: ketamine infusion at a dose of 0.1 mg/kg/hour for 16 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: ketamine infusion at a dose of 0.3 mg/kg/hour for 16 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Without ketamine
Study: NCT06294340

Intervention type: OTHER
Intervention: Exposure to loud pre-recorded road traffic noise
Description: Participants of both arms will be exposed to the same loud pre-recorded road traffic noise in a laboratory setting.

Intervention type: OTHER
Intervention: Exposure to loud pre-recorded road traffic noise
Description: Participants of both arms will be exposed to the same loud pre-recorded road traffic noise in a laboratory setting.
Study: NCT05894551

Intervention type: OTHER
Intervention: Evaluation of q angles different positions
Description: Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait

Intervention type: OTHER
Intervention: Physical examination
Description: With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6).
Study: NCT04506606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Afferent block
Description: Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
Study: NCT05894551

Intervention type: OTHER
Intervention: Functional mobility assessment
Description: 10-meter walking test will be conducted to understand functional mobility.
Study: NCT05452408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antitumor B KAC
Description: ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.
Study: NCT04951882

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: human derived umbilical cord derived mesenchymal stem cells
Description: intravenous transplantation of human derived umbilical cord derived mesenchymal stem cells
Study: NCT05457712

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protocol
Description: The energy and protein value of the prescribed diet will be followed according to the original protocol considering plans A, B or C, via a hypercaloric formula with a caloric density of 1kcal/ml for infants starting 60 days preoperatively. The return for nutritional monitoring will take place after evaluation: weekly, biweekly or monthly.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Afterwards, they will be evaluated through the standard nutritional protocol of the nutrition clinic of the Instituto de Cardiologia de and Hospital Santo Antonio de Porto Alegre, whose standard nutritional prescription is a polymeric formula with a caloric density of 0.67 kcal/ml. Nutritional monitoring will take place through telephone contact for information on the baby's clinical data and in person before the surgery is performed.
Study: NCT06107361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B. Braun 6.35cm 20 gauge ultralong intravenous catheter
Description: B Braun Medical Inc, 6.35cm 20 gauge ultralong intravenous catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD 5.71 cm 20 gauge Accucath
Description: Bard Access Systems, Inc, BD 5.71 cm 20 gauge ultralong intravenous catheter with guide wire